Inhibition of T cell activation and autoimmune diabetes using a B cell surface–linked CTLA-4 agonist
J. Clin. Invest. Brian T. Fife, et al. 116:2252 doi:10.1172/JCI27856 [
Go to this article.]

Figure 1
Tg
+
scαCTLA-4 expression.
Flow cytometric analysis was performed on splenocytes from scαCTLA-4 Tg
+ mice and littermate controls using soluble murine fusion protein mCTLA-4 Ig and anti-B220. (
A) Upper panels demonstrate scαCTLA-4 on naive Tg
+ B cells and activated Tg
+ B cells following anti-IgM stimulation (48 hours, 1 μg/ml) compared with FVB littermate negative controls (lower panels). All plots were gated on B220
+ B cells. (
B) Flow cytometric analysis was performed on thymocytes from scαCTLA-4 Tg mice and littermate controls as described above. Flow plots illustrate scαCTLA-4 expression in DP CD4
+CD8
+ thymocytes from scαCTLA-4 Tg
+ mice, but not DP CD4
+CD8
+ thymocytes from FVB or SP CD4
+ and SP CD8
+ from scαCTLA-4 Tg
+ or FVB Tg
– controls. Results shown are representative of 3 independent experiments with ≥ 3 mice per group.